Exercise Intervention Using mHealth in Patients With Post-Acute COVID-19 Syndrome: a Randomized Clinical Trial

Not Applicable

Recruiting

• Conditions: Post-Acute COVID19 Syndrome; Long COVID; Post COVID-19 Condition
• Interventions: Other: Control Group; Device: COVIDReApp Group

• Registration Number: NCT05725538
• Lead Sponsor: University of Cadiz

Brief Summary

Post-Acute Syndrome COVID-19 is a disease resulting from infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is estimated that between 10 and 35% of infected persons suffer symptoms afterwards, and in hospitalized patients it can reach 85%. These sequelae have individual, social and economic repercussions, so effective rehabilitation alternatives are necessary. Physical exercise is recommended as rehabilitation for these patients. Moreover, the implementation of m-Health supported interventions is a proven alternative in patients with Post-Acute COVID-19 Syndrome or other conditions, which improves therapeutic adherence and patient autonomy. Therefore, the development and evaluation of the effectiveness of an exercise-based m-Health system for application in patients with Post-Acute COVID-19 Syndrome responds to a need.

Our hypothesis is that a mobile health technology based on physical exercise recommendations for patients with Post-Acute COVID-19 Syndrome will improve fatigue, physical fitness, post-exertional dyspnea, pain intensity, anxiety, depression, cognitive function, and quality of life. Therefore, this project aims to evaluate the efficacy of the mobile health technology system (COVIDReApp) based on physical exercise recommendations for patients with COVID-19 Post-Acute Syndrome based on its results on fatigue, physical condition, post-exertional dyspnea, pain intensity, anxiety and depression, cognitive function and quality of life.

The achievement of the present project will serve to analyze the benefits of a physical exercise program in patients with COVID-19 Post-Acute Syndrome and identify those patients in whom the benefits will be greatest and whose implementation will have the highest priority.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-02
• Study First Submitted: 2023-02-07
• Study First Submitted QC: 2023-02-10
• Last Update Submitted: 2023-02-10
• Study First Posted: 2023-02-13
• Last Update Posted: 2023-02-13
• Study Start: 2023-03-15
• Primary Completion: 2024-03-15
• Study Completion: 2024-09-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Male and female patients.
• Over 18 years of age.
• Absence of cognitive and physical deficits that would preclude physical exercise.
• Owner of a smartphone with Internet access.
• Ability to understand and write in Spanish.

Exclusion criteria:

• Concomitant diseases that prevent physical exercise.
• Contraindications to physical exercise detected by physicians.
• Participation in moderate-intensity activities (more than 30 minutes and 3 times per week) at the time of study initiation.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Group	Control Group	The comparator group will complete a program of exercise in a traditional way (exercises will be provided in paper format) for 24 weeks.
COVIDReApp Group	COVIDReApp Group	The intervention group will complete a program of exercise guided by a m-health system (COVIDReApp) for 24 weeks.

Primary Outcome Measures

Name	Time	Method
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Fatigue (Fatigue Severity Scale (FSS))	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	The FSS consists of 9 items related to the interference of fatigue with specific activities and rates the perceived severity of fatigue on a 7-point scale (1 = "strongly disagree"; 7 = "strongly agree").
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Post-exertional dyspnoea (Dyspnoea-12)	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	Post-exertional dyspnea is assessed using the Dyspnea-12, a short questionnaire that takes into account both sensory and affective factors that may play a role in dyspnea. Each item in the questionnaire is scored from 0, if the symptom is mild, to 3, if it is severe, and the total score is the sum of the scores for all items. Six of the questions relate to sensory aspects and 6 to affective aspects of dyspnea. The total score ranges from 0 to 36, with 36 being the highest possible severity and 0 being the lowest.
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Quality of life (SF-12v2)	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	The Short Form-12 (SF-12v2) will be administered to assess quality of life. This instrument contains 12 items that allow us to calculate the profile of 8 dimensions: (physical functioning, role-physical, bodily pain, general health perception, vitality, social functioning, role-emotional, and mental health) and two global scores: the physical health (PCS-12) and the mental health (MCS-12) component summary. Each global score ranges from 0 to 100, with higher scores indicating better health.

Secondary Outcome Measures

Name	Time	Method
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Upper limb strength (Arm curl test)	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	The Arm Curl Test assesses upper body strength by determining the number of times a hand weight (2.3 kg) can be curled through a full range of motion in 30 seconds.
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Depression and/or anxiety (Hospital Anxiety and Depression Scale (HADs)	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	Depression and anxiety are assessed using the Hospital Anxiety and Depression Scale (HADS), which consists of 14 items divided into two subscales: anxiety (HADS-A) and depression (HADS-D).
Daily registry of the adherence (CovidReApp log registration and self-reported)	Daily.	The information is collected by the system only in the COVIDReApp group.
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Lower limb strength (Chair stand test)	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	The chair stand test evaluates lower body muscular strength by counting the number of times a person can go from a sitting position to a standing position in 30 seconds.
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Functional capacity and endurance (Two-minute walk test (2MWT))	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	The two-minute walk test (2MWT) assesses walking ability, functional endurance and functional capacity. It consists of measuring the distance the patient can walk for 2 minutes as fast as he or she can safely without assistance.
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Pain intensity (Visual Analog Scale (VAS))	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	VAS is a scale used to rate the patient's pain intensity. The patient chooses a number from 0 to 10 (11-point numeric scale) that represents the best level of pain that the patient can imagine. A score of 0 represents no pain and 10 represents the worst pain imaginable.
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Height, weight, and body mass index	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	Body measurements: height (standard height meter), weight, and body mass index (Tanita Model TBF-310 GS Weight Scale, Tanita Corporation of America, Inc., Arlington Heights, IL).
Daily registry of the exercise difficulty (Borg Rating of Perceived Exertion Scale (RPE))	Only CovidReApp group: Daily.	CovidReApp system will register the daily exercise, which allows us to know the exercise difficulty of each exercise.
Baseline of sociodemographic variables	Baseline.	A structured questionnaire will be used to collect sociodemographic data, including the following variables: gender, age, socioeconomic status, marital status, education level, employment status, clinical data, and use of alternative therapies.
Longitudinal Change from Baseline up to 24 Weeks Follow-up in Cognitive function (Test Your Memory (TYM))	Baseline, 4 weeks post-treatment, 12 weeks post-treatment, and 24 weeks post-treatment.	The Test Your Memory (TYM) screening test is used to assess cognitive function. This tool consists of 10 items with a total score ranging from 0 to 50, calculated on 10 cognitive dimensions: executive function, anterograde memory, visuospatial ability, naming, similarities, verbal fluency, calculation, retrograde memory, copying, orientation. The cut-off point is 42/50 (≤41 points indicates cognitive dysfunction) and a higher score indicates better cognitive performance.

Trial Locations

Locations (1)

Hospital Universitario Puerta del Mar; 🇪🇸 Cadiz, Spain